← All trials
NCT04475744
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 30, 2020
- Primary completion
- Oct 31, 2022
- Completion date
- Oct 31, 2024
- First posted
- Jul 17, 2020
- Last posted
- Nov 17, 2020
- Enrollment
- 42
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Fundación IVILead sponsor
- University of ValenciaCollaborator
- University of ValenciaCollaborator
- IVI MadridCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.